Plasma urate concentration and risk of coronary heart disease: A Mendelian randomisation analysis

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 4, 2016, Pages 327-336

  White, Jon ^a   Sofat, Reecha ^a   Hemani, Gibran ⁿ   Shah, Tina ^a   Engmann, Jorgen ^a   Dale, Caroline ^e   Shah, Sonia ^p   Kruger, Felix A ^a   Giambartolomei, Claudia ^a   Swerdlow, Daniel I ^a   Palmer, Tom ^k   McLachlan, Stela ^b   Langenberg, Claudia ^a,m   Zabaneh, Delilah ^a   Lovering, Ruth ^a   Cavadino, Alana ^l   Jefferis, Barbara ^a   Finan, Chris ^s   Wong, Andrew ^a   Amuzu, Antoinette ^e   Ong, Ken ^a,m   Gaunt, Tom R ⁿ   Warren, Helen ^d,o   Davies, Teri Louise ⁿ   Drenos, Fotios ^a,n   Cooper, Jackie ^a   Ebrahim, Shah ^e   Lawlor, Debbie A ⁿ   Talmud, Philippa J ^a   Humphries, Steve E ^a   Power, Christine ^l   Hypponen, Elina ^l,q,r   Richards, Marcus ^a   Hardy, Rebecca ^a   Kuh, Diana ^a   Wareham, Nicholas ^m   Ben Shlomo, Yoav ⁿ   Day, Ian N ⁿ   Whincup, Peter ^f   Morris, Richard ^a   Strachan, Mark W J ^j   Price, Jacqueline ^b   Kumari, Meena ⁱ   Kivimaki, Mika ^a   Plagnol, Vincent ^a   Whittaker, John C ^h   Smith, George Davey ⁿ   Dudbridge, Frank ^e   Casas, Juan P ^a,e   Holmes, Michael V ^c,g   Hingorani, Aroon D ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f ST GEORGE S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ UNIVERSITY OF ESSEX   (United Kingdom)

^j WESTERN GENERAL HOSPITAL   (United Kingdom)

^k UNIVERSITY OF WARWICK   (United Kingdom)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ UNIVERSITY OF BRISTOL   (United Kingdom)

^o QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^p UNIVERSITY OF QUEENSLAND   (Australia)

^q UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^r SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^s WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URATE; URIC ACID;

ARTICLE; DIASTOLIC BLOOD PRESSURE; GENETIC ASSOCIATION; HUMAN; ISCHEMIC HEART DISEASE; MENDELIAN RANDOMIZATION ANALYSIS; MULTIVARIATE ANALYSIS; PLEIOTROPY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; BLOOD; CORONARY DISEASE; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PROCEDURES; RISK FACTOR;

CORONARY DISEASE; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; META-ANALYSIS AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; RISK FACTORS; URIC ACID;

EID: 84954349711     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00386-1     Document Type: Article

References (28)

1. Terkeltaub RA Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010, 6:30-38.
2. Yang Q, Köttgen A, Dehghan A, et al. Multiple genetic loci influence serum urate and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010, 3:523-530.
3. Davis N The cardiovascular and renal relations and manifestations of gout. JAMA 1897, 29:261-262.
4. Wheeler JG, Juzwishin DM, Eriksdottir G, Gudnason V, Danesh J Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-Analysis. PLoS Med 2005, 2:236-243.
5. Waring WS, McKnight JA, Webb DJ, Maxwell SRJ Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006, 55:3127-3132.
6. Cory DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26:269-275.
7. Rajendra NS, Ireland S, George J, Belch JJF, Lang CC, Struthers AD Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 2011, 58:821-828.
8. Landmesser U, Drexler H Allopurinol and endothelial function in heart failure: future or fantasy?. Circulation 2002, 106:173-175.
9. Struthers A, Shearer F Allopurinol: novel indications in cardiovascular disease. Heart 2012, 98:1543-1545.
10. Stone PH Allopurinol: a new anti-ischemic role for an old drug. JACC 2001, 58:829-830.
11. Lawlor DA, Harbrod RM, Sterne JAC, Timpson N, Davey Smith G Mendelian randomisation: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008, 27:1133-1163.
12. Burgess S, Dudbridge F, Thompson SG Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol 2015, 81:290-291.
13. Bowden J, Davey Smith G, Burgess S Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015, 44:512-525.
14. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Met Med Res 2011, 21:223-242.
15. Shah T, Engmann J, Dale C, et al. Population genomics of cardiometabolic traits: design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium. PLoS One 2013, 8:e71345.
16. Sedaghat S, Pazoki R, Uitterlinden AG, et al. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension 2014, 64:1061-1066.
17. Johnson T Efficient calculation for multi-SNP genetic risk scores. American Society of Human Genetics Annual Meeting; San Francisco, CA, USA; Nov 6-10, 2012 (accessed Jan 6, 2016). http://cran.r-project.org/web/packages/gtx/vignettes/ashg2012.pdf.
18. Yates A, Beal K, Keenan S, et al. The Ensembl REST API: Ensembl data for any language. Bioinformatics 2015, 31:143-145.
19. Jain E, Bairoch A, Duvaud S, et al. Infrastructure for the life sciences: design and implementation of the UniProt website. BMC Bioinformatics 2009, 10:136.
20. Brion MJ, Shakhbazov K, Visscher PM Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013, 42:1497-1501.
21. Ashton KS, Andrews KL, Bryan MC, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. discovery of a novel tool compound for in vivo proof-of-concept. J Med Chem 2014, 57:309-324.
22. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 2013, 347:f4262.
23. Kleber ME, Delgado G, Grammer TB, et al. Uric acid and cardiovascular events: a Mendelian randomisation study. J Am Soc Nephrol 2015, 26:2831-2838.
24. Parsa A, Brown E, Weir MR, Fink JC, Shuldiner AR, Mitchell BD, McArdle PF Genotype-based changes in serum uric acid affect blood pressure. Kidney Int 2012, 81:502-507.
25. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999, 150:341-353.
26. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012, 379:1214-1224. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.
27. 2-IIA and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol 2013, 62:1966-1976.
28. Bento AP, Gaulton A, Hersey A, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res 2014, 42:1083-1090.